Corey B Marvel, MBA, COE
Mr. Marvel joined Retina Associates New Orleans in 2001 and serves as Chief Executive Officer for Retina Associates and The Foundation for Retinal Research. In addition to his financial management and regulatory responsibilities he continues to devote extensive time to local and national clinical research in vitreoretinal disease. He is an active member of The American Academy of Ophthalmic Executives, The American Society of Retina Specialists Practice Administrators, The American Society of Ophthalmic Administrators, The Medical Group Management Association, The Association for Research in Vision and Ophthalmology and The Association of Clinical Research Professionals.
He received his graduate credentials from The University of Alabama with postgraduate studies in business administration. He was honored with City Business’ Health Care Heroes award and selected as the inaugural recipient of The Marvel ARRT Scholarship Award. He obtained national certification from The Joint Commission of Allied Health Personnel in Ophthalmology and board certification from The American Board of Opticianry. He also holds NBCOE certification as a Certified Ophthalmic Executive, AAOE/IJCAHPO certification as a Certified Ophthalmic Coding Specialist and JCAHPO/ATPO certification for Ophthalmic Scribe. The International Who’s Who of Professional Management has recognized him for his accomplishments in the field of ophthalmic management.
In his senior management role with The Foundation for Retinal Research, Mr. Marvel pursues advancements in the diagnosis, management and treatment of ophthalmic diseases through ongoing clinical research and education. As Clinical Research Director and Investigator at The Foundation for Retinal Research in New Orleans, he joins a team of investigators and research professionals sharing his passion and goals. A member of a select team traveling to Bucharest with The American-Romanian Medical Relief Foundation, he helped secure equipment and supplies in advance of their arrival and extensively participating in the training and transfer of skills for both clinical and surgical personnel.
He is a member of The American Academy of Ophthalmic Executives, The American Society of Ophthalmic Administrator, The Association of Clinical Research Professional, The Association for Research in Vision and Ophthalmology and The Association for Technical Personnel in Ophthalmology.
Research Protocols as Investigator & Clinical Research Coordinator
March 2013 – present: Alcon Research OSPREY C-12-006; A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA in Subjects With Exudative Age-Related Macular Degeneration
July 2007 – July 2011: Regeneron Pharmaceuticals VIEW VGFT-OD-0605; A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration
June 2007 – September 2011: Allergan 206207-012-00; Posterior Segment Drug Delivery System Evaluating the Efficacy and Safety of Dexamethasone in the treatment of Diabetic Macular Edema
May 2007 – January 2013: Genentech RISE FVF4170g; A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus
September 2004 – September 2009: Diabetic Retinopathy Clinical Research Network; Evaluation of the Efficacy and Safety of Intravitreal Triamcinolone Acetonide compare to Laser Pan Retinal Photocoagulation for Diabetic Macular Edema
March 2004 – January 2009: Alcon Research AART C-02-60; A Phase III, 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months in Subjects with Dry Age-Related Macular Degeneration.
November 2004 – May 2007: Genentech PIER FVF3192g; A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Neovascular Age-Related Macular Degeneration
July 2004 – November 2005: Eyetech Pharmaceuticals EOP1010; An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration
July 2004 – January 2007: Eyetech Pharmaceuticals EOP 1011; A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion
July 2002 – June 2003: Oculex Pharmaceuticals DC103-06-02; Posterior Segment Drug Delivery System Evaluating the Efficacy and Safety of dexamethasone implant in Persistent Macular Edema
July 2002 – November 2005: Eyetech Pharmaceuticals EOP1004; Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration
July 2002 – May 2003: Bausch & Lomb Incorporated VIT-02-08961X; Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage
July 2002 – August 2003: National Eye Institute (NEI) The Collaborative Ocular Melanoma Study (COMS); A Phase III, long-term, multicenter, randomized controlled trial. In the trial for patients with tumors of medium size, enucleation and irradiation with an iodine-125 episcleral plaque are compared on the basis of length of remaining life. For patients randomly assigned to enucleation, the eye was removed following a standard procedure. For patients assigned to plaque irradiation, the margins of the tumor were located and the dimensions of the tumor were measured by the ophthalmic surgeon. A gold plaque with a plastic seed carrier that contained the proper dosage and configuration of radioactive iodine seeds was sutured to the outside (sclera) of the eye over the base of the tumor. This procedure made possible the delivery of a high dose of radiation to a very localized area (85 Gy [TG-43] to the tumor apex). The plaque typically was removed from the eye after three to seven days.
In the COMS trial of preoperative radiation, patients with large tumors were randomized to enucleation alone or to enucleation preceded by 20 Gy of external beam radiation. The two randomly assigned groups of patients were followed for at least five years or until death and have been compared on the basis of length of remaining life and other outcomes.
Accrual to a nonrandomized pilot study to assess the feasibility of a randomized trial for small tumors was halted in 1989. Additional followup of those 204 patients was carried out from 1994 to 1996.
The COMS is conducted in 43 clinical centers located in major population areas of the United States and Canada. Six resource centers participate and have major roles in quality assurance for the study. Information gathered and analyzed includes time to death from all causes, time to death from cancer (whether metastatic choroidal melanoma or not), diagnosis of other tumors, complications of radiation, and changes in visual acuity. A parallel study of quality of life for patients enrolled in the trial of radioactive plaque was initiated in January 1995. From November 1986 through July 1998, 8,712 patients with choroidal melanoma of all sizes were screened for eligibility for a COMS clinical trial.
Certifications and Training
Medidata Rave Electronic Data Capture Training, March 2013
Osprey Investigator Meeting, Dallas Texas, March 2013
Certified Clinical Research Coordinator, April 2007
CPR and BLS Certified, 2001 – present
HIPAA Compliance and Security Officer, 2001 – present
New Orleans Academy of Ophthalmology Annual Symposium, 2001 – present
International Air Transport Association, 1997 – present
Good Clinical Practices, 1997 – present
Medicare and Medicaid Compliance, 1997- present
OSHA Compliance and Safety, 1997 – present
American Academy of Ophthalmology Annual Symposium, 1992 – present
Joint Commission on Allied Health Professionals, 1992 – present
Ophthalmic Medical Technologist, 2005 – present
Professional Registered Optician, 1999 – 2005
Certified Ophthalmic Technician, 1999 – 2005
VISX Star Excimer Laser System, Certified System Operator, April 1999
Certified Ophthalmic Assistant, 1995 – 1999
American Board of Opticianry Certified, 1995 – 2005
Medical Group Management Association, 2011
Association of Clinical Research Professionals, 2010
Association for Research in Vision and Ophthalmology, 2001
Association of Clinical Research Professionals, 2001
American Academy of Ophthalmic Executives, 1999
American Society of Ophthalmic Administrators, 1999
Opticians Association of America, Honored Fellow, 1996
Contact Lens Society of America, 1996
Association of Technical Personnel in Ophthalmology, 1995
Joint Commission on Allied Health Personnel in Ophthalmology, 1995
National Academy of Opticianry, Fellow, 1995